|

Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy

RECRUITINGN/ASponsored by Erasmus Medical Center
Actively Recruiting
PhaseN/A
SponsorErasmus Medical Center
Started2025-02-03
Est. completion2027-09
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06720636

Summary

The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Any participant 18 years and above, with ultralong-segment Barrett's esophagus and clinically fit for an endoscopy
* Ability to provide informed consent

Exclusion Criteria:

* Individuals with a diagnosis of an oro-pharynx, esophageal or gastro-esophageal tumor (T2 staging and above), or symptoms of dysphagia
* Esophageal varices or stricture requiring dilatation of the esophagus
* Individuals who have had a cerebrovascular event \< 6 months prior where their swallowing has been affected
* Patients who have had previous treatments such as Photodynamic therapy (PDT), Radiofrequency ablation (RFA) or Argon Plasma Coagulation (APC) for dysplastic Barrett's esophagus
* Participants who are unable to provide informed consent
* Participants under age 18 years

Conditions2

Barrett EsophagusCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.